CMX001 in Post-transplant Patients With BK Virus Viruria

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.

Study Overview

• Status: Completed
• Conditions: Viruria
• Intervention / Treatment: Drug: Placebo; Drug: Brincidofovir

Detailed Description

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection.

Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens:

• 10 mg BCV administered twice weekly (BIW) on Days 0, 3, 7, 10, 14.
• 20 mg BCV administered once weekly (QW) on Days 0, 7, and 14 and placebo administered on Days 3 or 10.
• Placebo administered BIW on Days 0, 3, 7, 10 ,14.
• 40 mg BCV administered QW on Days 0, 7, 14, 21, and 28.
• Placebo administered QW on Days 0, 7, 14, 21, and 28.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94115
      • California Pacific Medical Center
    • San Francisco, California, United States, 94143-0780
      • University of California, San Francisco
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • Tulane Center For Abdominal Transplant
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins Medical Institutions
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Beth Israel Deaconess Medical Center
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • New York
    • New York, New York, United States, 10029
      • Mt. Sinai Medical Center
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • UNC Kidney Center
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest University Health Sciences
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15260
      • University of Pittsburgh
  • Vermont
    • Burlington, Vermont, United States, 05405
      • University of Vermont
  • Washington
    • Seattle, Washington, United States, 19024
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 71 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

For inclusion into the trial, subjects were required to fulfill all of the following criteria:

1. Aged between 18 to 75 years, inclusive. Males must have been able and willing to use adequate contraceptive methods throughout the study and for 3 months after the final dose. Females must have been post-menopausal, surgically sterile, or willing to use adequate contraception for the duration of the study (screening through the Day 48 visit).

2. Were renal or hematopoietic stem cell transplant patients who met the following criteria:

   1. Renal transplant patients who:

      • Were at least 28 days post transplant;
      • Were in stable condition with hemoglobin >10 g/100 mL;
      • Had no evidence of graft rejection (i.e., serum creatinine was not increasing [±30%], creatinine clearance was not decreasing);
      • Were on a stable immunosuppressant regimen for at least 14 days prior to dosing.
      • Had either urine levels of BK virus DNA ≥10^4 copies/mL without viremia or plasma levels of BK virus DNA <10^4 copies/mL (with or without viruria).

   2. Stem cell transplant patients who:

      • Were a minimum of 3 days post documentation of successful engraftment as evidenced by an absolute neutrophil count >500 cells/mm3;
      • Had urine levels of BKV ≥10^4 copies/mL.
3. Had GFR >30 mL/min.
4. Were able to swallow tablets.
5. Were willing and able to understand and provide written informed consent.
6. Were willing and able to participate in all required study activities for the duration of the study (including ingestion of oral medication).

Exclusion Criteria

Any of the following was regarded as a criterion for exclusion from the trial:

1. Females who were currently nursing or pregnant.
2. Were using illicit drugs or abusing alcohol.
3. Had hypersensitivity to cidofovir or brincidofovir.
4. Had received aminoglycosides (intravenously) or NSAIDS (except as given for cardioprotective treatment) within 7 days prior to enrollment; had received leflunomide, cidofovir, or any other medication for treatment of BK virus infection or disease within 14 days prior to enrollment; had received any investigational drug (including maribavir) within 30 days prior to enrollment.
5. Were HIV positive (results must have been obtained within 1 year prior to dosing); had active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection as evidenced by plasma levels of HCV RNA or HBV DNA, respectively.
6. Were renal transplant patients with evidence of biopsy proven acute rejection in the 3 weeks prior to enrollment. This exclusion criterion applied only to those patients for whom a biopsy was performed within the 3 weeks prior to enrollment.

7. Were stem cell transplant patients who:

   1. Had cystitis ≥Grade 3 National Cancer Institute, Common Terminology Criteria for Adverse Events version 3.0.
   2. Had Grade 3 or 4 graft versus host disease (GVHD).
   3. Had untreated or uncontrolled Grade 2 GVHD.
   4. Had received ganciclovir or valganciclovir within 14 days prior to enrollment.
8. Had mucositis that prevented ingestion of oral medication.
9. Had hypotony, uveitis, or retinitis or any intraocular pathology that would have predisposed the patient to any one of these conditions.
10. Had unstable or poorly controlled diabetes, defined as having frequent hypoglycemic and/or hyperglycemic events on a daily basis (brittle diabetes), with fluctuating short acting insulin requirements daily, or requiring unpredictable insulin supplementation to oral hypoglycemic agents on a regular basis.
11. Had bilirubin >2.5 x the upper limit of normal.
12. Had cardiovascular disease which, in the opinion of the investigator, would have interfered with the conduct of the study.
13. Had any of the following autoimmune diseases: Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid, celiac disease, dermatomyositis, active Goodpasture's syndrome, idiopathic thrombocytopenic purpura, active lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, polymyositis, primary biliary cirrhosis, vasculitis, Wegener's granulomatosis.
14. Had active malignancies (with the exception of basal cell carcinoma or the condition under treatment for hematopoietic stem cell transplant patients).
15. Had concurrent or ongoing ≥Grade 2 gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, or gastroenteritis. Patients with active gastrointestinal disease including inflammatory bowel disease, irritable bowel syndrome, or celiac sprue.
16. Had any other condition including abnormal laboratory values that would have, in the judgement of the investigator, put the subject at increased risk for participating in the trial, or interfered with the conduct of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Brincidofovir; Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows: 20 mg BCV once weekly (QW) on Days 0, 7, and 14; or; 10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28.	Drug: Brincidofovir; Other Names: BCV; CMX001
Placebo Comparator: Placebo; Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28.	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria	The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.	35 days (Day 0 to Day 35)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients Who Achieved BK Viruria Resolution	The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".	28 days
Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria	A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.	28 days

Collaborators and Investigators

• Sponsor: Chimerix

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2009
• Primary Completion (Actual): October 1, 2010
• Study Completion (Actual): October 1, 2010

Study Registration Dates

• First Submitted: November 17, 2008
• First Submitted That Met QC Criteria: November 18, 2008
• First Posted (Estimate): November 19, 2008

Study Record Updates

• Last Update Posted (Actual): August 16, 2021
• Last Update Submitted That Met QC Criteria: July 19, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: Kidney transplant; BK Virus; CMX001; HSCT transplant; Post kidney transplant patients with BK virus viruria > 10^4; Post HSCT transplant patients with BK virus viruria > 10^4
• Additional Relevant MeSH Terms: Anti-Infective Agents; Antiviral Agents; Brincidofovir
• Other Study ID Numbers: CMX001-104